2093387-36-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione is used as a research compound for the development of novel therapeutics. Its ability to recruit the CRBN protein makes it a valuable tool in the design and synthesis of new drugs targeting specific proteins for degradation, which can be beneficial in the treatment of various diseases.
Used in PROTAC Research:
In the field of protein degradation, 3-(4-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione is used as a key component in the development of PROTACs. These are bifunctional molecules that facilitate the targeted degradation of specific proteins by recruiting the cellular machinery responsible for protein degradation. The compound's ability to recruit the CRBN protein makes it a promising candidate for the development of new PROTACs with potential applications in the treatment of various diseases, including cancer and neurodegenerative disorders.
Used in Drug Design and Synthesis:
3-(4-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione is also used as a building block in the design and synthesis of new drugs. Its unique structure allows for the creation of novel compounds with potential therapeutic applications. Researchers can use 3-(4-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione to develop new drugs that target specific proteins, leading to more effective treatments for a wide range of diseases.

Upstream product

• 99548-54-6 methyl 3-bromo-2-methylbenzoate 
• 24666-56-6 rac-α-aminoglutarimide hydrochloride 
• 337536-14-8 methyl 3-bromo-2-(bromomethyl)benzoate 
• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 2686-86-4 3-aminopiperidine-2,6-dione hydrochloric acid salt 
• 2353-44-8 (+/-)-α-aminoglutarimide 

Relevant academic research and scientific papers

A Buchwald–Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3-Ligase PROTACs**

A palladium-catalysed Buchwald–Hartwig amination for lenalidomide-derived aryl bromides was optimised using high throughput experimentation (HTE). The substrate scope of the optimised conditions was evaluated for a range of alkyl- and aryl- amines and functionalised aryl bromides. The methodology allows access to new cereblon-based bifunctional proteolysis targeting chimeras with a reduced step count and improved yields.

COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION

The invention provides cereblon binders for the degradation of proteins by the ubiquitin proteasome pathway for therapeutic applications.

PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases

Glycogen synthase kinase 3β (GSK-3β) is involved in a variety of diseases such as neurodegenerative diseases, bipolar disorder, and diabetes. In this study, a series of heterobifunctional small molecule proteolysis targeting chimera (PROTAC) were designed and synthesized based on E3 ubiquitin ligase cereblon (CRBN). Most of PROTACs displayed good inhibitory activity, with the IC50 values at the double-digits nanomolar levels and moderate protein degradation ability against GSK-3β. Western-blot data showed compound PG21 can effectively degrade GSK-3β in a dose-dependent manner, which can induce 44.2% protein degradation at 2.8 μM. Further pharmacological experiments revealed that the ability of PG21 to degrade GSK-3β is mediated by the ubiquitin-proteasome system (UPS). In addition, PG21 protects against glutamate-induced cell death in HT-22 cells. As the first PROTAC example to degrade GSK-3β protein, the present study has provided potential candidates for further investigation in the biological function of GSK-3β protein and its association with diseases.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

SMALL MOLECULE MDM2 PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.

Sulfur-containing compound based on glutaryl imide skeleton and application of compound

The present disclosure relates to compound shown in a formula (I) or salts, solvates, isotope-enriched analogs, tautomers, polymorphs, stereoisomers, or mixtures of stereoisomers of the compound, andthe application thereof in the treatment of tumours. The present disclosure also provides tumor treatment application of the compound showed in a formula (I') or pharmaceutically acceptable salts, solvates, isotope-enriched analogs, tautomers, polymorphic substances, stereoisomers, or mixtures of stereoisomers of the compound.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Isoindoline compound, and preparation method, pharmaceutical composition and application thereof

The invention relates to a polysubstituted isoindoline compound represented by a general formula (I), and a preparation method, a pharmaceutical composition and an application thereof. Specifically, as a CRL4CRBNE3 ubiquitin ligase regulator with a novel structure, the polysubstituted isoindoline compound provided by the invention has stronger anti-tumor activity and an anti-tumor spectrum, and can be used for preparing medicines for treating diseases related to CRL4CRBNE3 ubiquitin ligase.

Preparation method of target BTK protein degradation compound, and application of compound in treating autoimmune diseases and tumors

The invention provides a compound, the compound is a compound represented by a formula I, and a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceuticallyacceptable salt and prodrug of the compound represented by the formula I. The compound has a strong degradation effect on wild-type BTK, has no inhibition or degradation effects on other targets suchas EGFR, ITK, TEC, and the like, and has an effect of specific targeted degradation of BTK proteins. The formula I is X-Y-Z.